



Through our in-house developed Smart-ACT™ program, we are revolutionising the drug repurposing and repositioning industries; with a particular focus in servicing orphan diseases and unmet medical needs. With invaluable resource support from our ultimate parent company, Aptorum Group Limited (Nasdaq: APM), coupled with hybrid technology driven solutions, we are securing a perpetual pipeline for the generation of impactful drug candidates and therapeutic innovation into the future!

CHALLENGES

Traditionally, drug discovery and development ("3D") is a time-consuming, costly and high-risk business

TIME



10-17 YEARS¹

COST



USD 2.6 BILLION²

FAILURE RATE

86.2%

nearly 86.2%³ of drug candidates entering phase 1 trials fail to achieve drug approval

SMART-ACT™

Accelerating the Commercialisation of Therapeutics



Using **Computational Algorithms & Big Data**



Revolutionising **Drug Repurposing & Repositioning**



Focusing on **Orphan Diseases & Unmet Medical Needs**

COMPETITIVE ADVANTAGE



Reduce Development Time by ~8 Years



Lower Cost by over 90%



Higher Success Rate

	Traditional 3D - Problems	Act 3D - Solutions
Time (years)	10-17 years ¹ Drug Discovery: 3-10 years ⁴ Preclinical stage: 1 year Phase I: Several Months ⁵ Clinical stage: 5.4 years ⁶	5-6.5 years Drug Discovery: 1-1.5 years Preclinical Development: May not needed Phase 1: May not needed Phase 2 to market: 3.9 years ⁶
Cost	US\$2.6 billion ²	US\$33 million ⁷
Probability	Low hit rate from discovery to commercialisation	Expect 5 - 10 candidates to potentially enter clinical trials every year Higher probability of success 30% approval rate for repurposed drugs ⁸

¹<http://www.totalbiopharma.com/2012/07/04/4-key-benefits-drug-repositioning>; ²<https://www.the-scientist.com/features/repurposing-existing-drugs-for-new-indications-32285>;


³<https://academic.oup.com/biostatistics/article/20/2/273/4817524>; ⁴Estimated based on the overall development time of 10-17 years;

⁵<https://www.fda.gov/forpatients/approvals/drugs/ucm405622.htm>; ⁶Source: Drug Discov Today. 2012;17(13-14):660-4.; ⁷Source: Key cost drivers of pharmaceutical clinical trials in the United States (PDF), pg 5 (121), Oncology.; <https://www.ncbi.nlm.nih.gov/pubmed/26908540>;

⁸<https://www.dcatvci.org/11-value-chain-insights/114-drug-repurposing-and-repositioning-making-new-out-of-old#>

VALUATION OF SMART-ACT™ 1

- Est. # Cumulative New Candidates Emerging From Validation; lhs
- Est. # Cumulative Clinical Assets in Pipeline; lhs
- Projected Mid-range Valuation (US\$bn); rhs



Early opportunities for out-licensing of clinical asset

POTENTIAL OF ACT

Orphan Diseases

7000

Pipeline

- 5-10¹ candidates potentially enter clinical trials each year
- Expect 1st clinical asset in 2020 and cumulatively 4 clinical assets by 2023¹

Potential Asset Pipeline Valuation

- Projected mid-range value at US\$42 billion¹ by 2023

Clinical Development Costs (Wet-lab, Phase 2, Phase 3)

- US\$ 33 million² per cancer drug
- US\$ 120 million¹ accumulated development costs by 2023

Return on Invested Capital

- Per drug candidate: 4x to 5x (over 4 years)¹

Perpetual pipeline:

Systematic pipeline of clinical assets targeting orphan diseases and unmet medical needs!

ABOUT SMPT

Token Symbol

SMPT

Token Type

ERC-1404 security compliant tokens with ERC-20 and ERC-233 compliance on the Ethereum blockchain

Total Token Supply

1,000,000,000 (100%)

Tokens available for Public

700,000,000 (70%)

Retention by Issuer's staff, partners and ecosystem

50,000,000 (5%)

Retention by Issuer

250,000,000 (25%)

Secondary Market

To be disclosed

Issuer

Smart Pharmaceutical Limited Partnership


Technology Partner

SMPT token is co-developed together with Aenco Solutions (www.aencoin.com)

SMART PHARMA TOKEN (SMPT)

PROJECTED SMPT INTRINSIC VALUE (US\$) PER TOKEN^{1,3}

- Est. # Cumulative New Candidates Emerging From Validation; rhs
- Est. # Cumulative Clinical Assets in Pipeline; rhs
- Mid-point SMPT token value; lhs



Token price upon issuance: US\$0.05 - 0.10

info@smtph.com

Smart Pharma Community is jointly managed in collaboration with Aenco Solutions Limited



aencoin



aencoin



aenco



AENCO




aencoin



Aenco

¹ Smart Pharma internal estimates based on model assumptions. Details available upon request; ² <https://www.ncbi.nlm.nih.gov/pubmed/26908540>; ³ Per token value is calculated based on the total SMPT supply of 1,000,000,000 tokens, and is adjusted for a projected pass-through of 5% and 15% of market value to SMPT token holders, for value deriving from commercialisation and out-licensing strategies respectively.

Disclaimer: Value projections are illustrative only. All estimates and forward-looking projections are based on modeled assumptions, which we believe to be reasonable, and evidence based where applicable. However, such assumptions are subject to change based on newly emerging data and/or evidence, which could lead to changes in some or all projections presented in this leaflet. We disclaim any responsibility to update these projections in the event of such changes at any time in the future.



WWW.SMTPH.COM